Patents by Inventor Abdul Quddus

Abdul Quddus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors
    Patent number: 11987573
    Abstract: Compounds of formula (I), and related aspects.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: May 21, 2024
    Assignee: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Emma Blackham
  • SYNTHESIS OF CATHODE MATERIAL FOR LITHIUM BATTERY
    Publication number: 20240150177
    Abstract: A synthesis method of cathode material for lithium battery is provided. The method includes dissolving lithium, nickel and cobalt acetate in a solution, adding ammonium dihydrogen phosphate to the solution, adding acid to the solution, heating the solution to a first temperature for a first period of time to form a solid mixer material, and sintering the solid mixer material at a second temperature for a second period of time.
    Type: Application
    Filed: November 6, 2023
    Publication date: May 9, 2024
    Applicant: Qatar University
    Inventors: Abdul Shakoor, Umair Nisar, Zawar Qureshi, Jeffin Abraham, Khadija Muhammad Abdul Quddus, Siham AlQaradawi, Ramazan Kahraman
  • Aminothiazole Compounds as Inhibitors of CTPS1
    Publication number: 20240010645
    Abstract: Compounds of formula (I): (I) and related aspects.
    Type: Application
    Filed: April 18, 2023
    Publication date: January 11, 2024
    Inventors: Abdul QUDDUS, Andrew NOVAK, David COUSIN, Elli CHATZOPOULOU, Emma BLACKHAM, Geraint JONES, Jennifer THOMAS, Joesph WRIGGLESWORTH, Lorna DUFFY, Louise BIRCH, Pascal GEORGE, Saleh AHMED
  • Compounds
    Publication number: 20230192673
    Abstract: Compounds of formula (I): and related aspects.
    Type: Application
    Filed: November 3, 2022
    Publication date: June 22, 2023
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Aminothiazole compounds as inhibitors of CTPS1
    Patent number: 11655246
    Abstract: Compounds of formula (I): (I) and related aspects.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 23, 2023
    Assignee: STEP PHARMA S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Elli Chatzopoulou, Emma Blackham, Geraint Jones, Jennifer Thomas, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
    Publication number: 20230086703
    Abstract: Compounds of formula (I) wherein ring B is selected from the group consisting of Formula (B-a) and Formula (B-bc) as human cytidine triphosphate synthase 1 (CTPS 1) inhibitors for the treatment of proliferative diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 129 to page 302; examples; biological examples 1 and 2; tables 1-17). Specific examples are e.g.: N-(4-(5-Chloropyridin-3-yl)phenyl)-2-(2-(cyclopropane-sulfonamido) pyrimidin-4-yl)butanamide (Formula P1) or 1-(2-(Cyclopropanesulfonamido)pyrimidin-4-yl)-N-(4-(6-ethoxypyrazin-2-yl)phenyl)cyclopentanecarboxamide (Formula P2).
    Type: Application
    Filed: June 4, 2020
    Publication date: March 23, 2023
    Applicant: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Ellie Chatzopoulou, Geraint Jones, Jennifer Thomas, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed, Gianna Toschi
  • SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS
    Publication number: 20230020663
    Abstract: The invention provides a compound of formula (I) and processes for the manufacture of such compounds, related intermediates, compositions comprising such compounds and the use of such compounds as cytidine triphosphate synthase 1 inhibitors, particularly in the treatment or prophylaxis of disorders associated with cell proliferation.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 19, 2023
    Applicant: Step Pharma S.A.S.
    Inventors: Andrew Novak, Abdul Quddus, David Cousin, Joseph Wrigglesworth, Emma Blackham, Geraint Jones, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS
    Publication number: 20230002352
    Abstract: The invention provides a compound of formula (I): formula (I) and the use of such compounds as cytidine triphosphate synthase 1 inhibitors, particularly in the treatment or prophylaxis of disorders associated with cell proliferation.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 5, 2023
    Applicant: Step Pharma S.A.S.
    Inventors: Andrew Novak, Abdul Quddus, David Cousin, Joseph Wrigglesworth, Emma Blackham, Geraint Jones, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
    Publication number: 20220324837
    Abstract: Compounds of formula (I) as human cytidine triphosphate synthase 1 (CTPS1) inhibitors for the treatment of prolifera-tive diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisa-tion of exemplary compounds as well as pharmacological data thereof (e.g. pages 64 to 80; examples; biological examples 1 and 2; e.g. compounds P140, P231 to P263; tables 1 to 10). Specific examples are e.g.: N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonami-N do) pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (Formula (II)), or 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (Formula (III)).
    Type: Application
    Filed: June 4, 2020
    Publication date: October 13, 2022
    Applicant: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Compounds
    Publication number: 20210387965
    Abstract: Compounds of formula (I), and related aspects.
    Type: Application
    Filed: October 23, 2019
    Publication date: December 16, 2021
    Applicant: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Pharmaceutically Active Compounds
    Publication number: 20210070708
    Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Application
    Filed: July 14, 2020
    Publication date: March 11, 2021
    Applicant: BerGenBio ASA
    Inventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
  • Compounds
    Publication number: 20210024507
    Abstract: Compounds of formula (I): and related aspects.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 28, 2021
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • COMPOUNDS
    Publication number: 20210002269
    Abstract: Compounds of formula (I): (I) and related aspects.
    Type: Application
    Filed: November 11, 2018
    Publication date: January 7, 2021
    Inventors: Abdul QUDDUS, Andrew Novak, David COUSIN, Elli CHATZOPOULOU, Emma BLACKHAM, Geraint JONES, Jennifer Thomas, Joesph WRIGGLESWORTH, Lorna DUFFY, Louise BIRCH, Pascal GEORGE, Saleh AHMED
  • Pharmaceutically active compounds
    Patent number: 10766861
    Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: September 8, 2020
    Assignee: BerGenBio ASA
    Inventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
  • Pharmaceutically Active Compounds
    Publication number: 20200010421
    Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Application
    Filed: May 15, 2019
    Publication date: January 9, 2020
    Applicant: BerGenBio ASA
    Inventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
  • Pharmaceutically active compounds
    Patent number: 10336702
    Abstract: The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: July 2, 2019
    Assignee: BerGenBio ASA
    Inventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
  • PHARMACEUTICALLY ACTIVE COMPOUNDS
    Publication number: 20180029985
    Abstract: The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Application
    Filed: December 23, 2015
    Publication date: February 1, 2018
    Applicant: BERGENBIO AS
    Inventors: Jason John SHIERS, John Paul WATTS, Stuart Thomas ONIONS, Mohammed Abdul QUDDUS, Joseph William WRIGGLESWORTH, Colin Peter SAMBROOK-SMITH, Alan NAYLOR, Derek LONDESBROUGH
  • Neighbor list control for a wireless communication system
    Patent number: 8060100
    Abstract: A control system processes a first neighbor list for a first base station to identify a second base station and a third base station. The control system processes a second neighbor list for the second base station and a third neighbor list for the third base station to determine if the second base station is on the third neighbor list and if the third base station is on the second neighbor list. The control system processes wireless coverage data for the second base station and the third base station to determine if a wireless coverage overlap exists between the second base station and the third base station. If the overlap exists and if one of the base stations is not on the other base station's neighbor list, then the control system indicates that the missing base station should be added to the other base station's neighbor list.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: November 15, 2011
    Assignee: Sprint Communications Company L.P.
    Inventors: Abdul Quddus Rana, Syed Hassan Raza
  • Gamma-secretase inhibitors
    Patent number: 7452899
    Abstract: Compounds of Formula (I): inhibit the processing of APP by gamma-secretase, and hence are useful for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: November 18, 2008
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Michela Bettati, Amanda Louise Boase, Ian Churcher, Tamara Ladduwahetty, Kevin John Merchant, Abdul Quddus
  • Treatment for Alzheimer's Disease and Related Conditions
    Publication number: 20080153817
    Abstract: Compounds of formula (I): are useful in the treatment of diseases associated with deposition of ?-amyloid in the brain.
    Type: Application
    Filed: July 29, 2004
    Publication date: June 26, 2008
    Inventors: Dirk Beher, Michela Bettati, Graham David Checksfield, Ian Churcher, Victoria Alexandra Doughty, Paul Joseph Oakley, Abdul Quddus, Martin Richard Teall, Jonathan David Wrigley